Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(25)
•••
Comment by Blazesbon Jun 09, 2020 11:53pm
246 Views
Post# 31131772

RE:RE:RE:RE:RE:People's Poll - Adjusting for Risk - Market Price June 10

RE:RE:RE:RE:RE:People's Poll - Adjusting for Risk - Market Price June 10
whc wrote: I'll be happy if the price can stay at .4 or higher tomorrow.  I'm pretty sure the price dropped below financing price the last two financings.

I also don't buy the argument that they need the money to talk to big pharma from a position of strength.  That is why you talk to multiple companies.  Any good negotiator would play the companies off against each other.  If this drug is as good as they say it is, why wouldn't every company want it?  Didn't Dan say a while back that their data room was really busy, that a lot of companies were interested in the drug?  What's changed?

They don't need the money to 'talk to big pharma from a position of strength'.  They need the money to keep the lights on, advance to phase 3, ensure the door is always open to licensing discussions.  

We're staring a big recession in the face; The markets are in a bear market rally.  In this climate big pharma's bankrolls will not be brought out to buy just anything.  Way more 'show me the data' needed to loosen their purse strings.

Things have changed.  Antibe mgmnt behaved despicably selling into strength pre-data.  Going forward the 25 mil ensures they stay in the game prepared for whenever opportunity knocks.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities